Navigation Links
NIH, Gates Foundation and Colorado State team up to find new approach to a TB vaccine
Date:1/25/2011

WHAT: A team of U.S. and European researchers have found that a new vaccine strategy tested in mice provides stronger, more long-lasting protection from tuberculosis (TB) infection than the vaccine currently used in humans, known as BCG. Their findings were published online on January 23rd in the journal Nature Medicine.

The study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Bill & Melinda Gates Foundation. It was coordinated by the NIAID-funded TB Vaccine Testing and Research Materials program at Colorado State University, an initiative to speed the development of new TB vaccines and treatments.

Caused by the bacterium Mycobacterium tuberculosis (Mtb), TB remains one of the major causes of disability and death worldwide, with an estimated 1.7 million deaths in 2009 and increasing rates of drug-resistant disease. The BCG vaccine, the only one approved for human use, provides some protection against initial TB illness but does not prevent latent infection, in which Mtb persists in human cells for years and may later develop into active disease.

In this study, the researchers combined two proteins previously found to improve the BCG vaccine's effectiveness with a new component, a stress response protein that mice produce throughout the TB infection process. This three-component vaccine, known as H56, was administered to uninfected mice before and after BCG vaccination. Six weeks later, the mice were exposed to Mtb. The multistage strategy not only protected against initial illness, but controlled reactivation of latent infection and reduced Mtb levels in the lungs more effectively than BCG alone. Because of the success of this study, the vaccine candidate is now entering clinical development.


'/>"/>

Contact: Nalini Padmanabhan
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1

Related medicine news :

1. Ghrelin mitigates liver fibrosis in animal models; regulates human fibrosis
2. Bill & Melinda Gates, Asian Parliamentary Group, Win 2010 United Nations Population Award
3. Long Island Press Investigates Big Tobacco's Lobby to Kill Indian Cigarette Trade
4. SC Johnson and Bill & Melinda Gates Foundation Unite to Combat Malaria
5. Food Safety Law Firm Investigates Major Outbreak of E. coli Linked To Lettuce
6. Georgia Tech awarded Gates Foundation grant for innovative global health research
7. Drug mitigates toxic effects of radiation in mice
8. AIDS 2010 delegates and speakers unite in support of full funding for the Global Fund, the next milestone in drive for universal access
9. Thesis investigates characteristics of society using sports activities as research tool
10. UI study investigates variability in mens recall of sexual cues
11. BUSM investigates cellular mechanisms leading to immune response in airway epithelium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... , ... August 23, 2017 , ... ... to support long-term strategic growth plans, announcing the hiring of Kevin Keelan as ... technology consultant and seasoned sales manager, Keelan will be working with Virsys12 senior ...
(Date:8/22/2017)... CA (PRWEB) , ... August 22, 2017 , ... ... accessible luxurious collection of unique masks and serums that perfectly fuse the beauty ... care advancements, at the 2017 Indie Beauty Expo on August 23rd & 24th ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pleased to announce the addition of Zack Tisch as the firm’s new Consulting ... KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor ...
(Date:8/22/2017)... ... ... Glass is new to the Texas market, but is proudly managed by widely recognized All ... models, in Grand Prairie, TX, located in the center of the DFW Metroplex, the fourth ... for the past 40 years with 32 convenient locations in Texas, Nevada and California resulting ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... “Covert Awakening” is the creation of published author, Julianne Hale, a consultant ... as a policy and counter-terrorism expert focusing on the Near East region. ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)...   Second-quarter 2017 revenues of ... share from continuing operations ... to $110 million Second-quarter ... million Second-quarter 2017 adjusted ... 8 percent to $0.93 ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
Breaking Medicine Technology: